Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor

Inflammatory Myofibroblatic Tumor Clinical Trial

Official title:

Study on the Molecular Profile and Molecular Signature of Inflammatory Myofibroblastic Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04572594
• Other study ID #: Molecular profiling of IMT
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: September 2020
• Source: Sun Yat-sen University
• Contact: Dongsheng Zhang, PhD
• Phone: 86-2087343795
• Email: zhangdsh[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gene mutation is a research hotspot in the occurrence of multiple malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of genes related to inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.

Description:

Inflammatory myofibroblastic tumor（IMT）is a rare clinical mesenchymal tissue-derived tumor, which can occur in almost all organs and soft tissues, and is characterized by low-grade or borderline tumors.

The diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. The treatment is resistant to conventional chemotherapy and radiotherapy. The only curative treatment is complete surgical resection. When IMT shows typical cellular structural features in pathology, the diagnosis is relatively simple. However, in the presence of atypical features, the accurate diagnosis of IMT is still a challenge. Therefore, it is necessary to explore a better diagnostic method. Secondly, there is no individualized treatment method for aggressive IMT patients who relapse and metastasize after surgery. At present, gene mutation is a research hotspot in the occurrence of various malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 29
• Est. completion date: January 1, 2021
• Est. primary completion date: January 1, 2021
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. From December 2009 to July 2019, patients who were pathologically diagnosed with inflammatory myofibroblastic tumor by Sun Yat-sen University Cancer Center;

2. There are related pathological tissue wax blocks in Sun Yat-sen University Cancer Center;

3. Patient clinical and prognosis tracking data are available.

Exclusion Criteria:

The patient who has a clinically detectable second primary malignant tumor.

Related Conditions & MeSH terms

• Inflammatory Myofibroblatic Tumor

Locations

Country	Name	City	State
China	Cancer center of SunYat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establishing gene mutation spectrum of patients with inflammatory myofibroblastic tumor	We sequenced the genes in tissue samples from patients with inflammatory myofibroblastic tumor, and then analyzed the data to obtain a gene map of this type of tumor, and provide data support for the diagnosis and treatment of the disease.	through study completion,an average of 1 year
Secondary	Exploring molecular markers for inflammatory myofibroblastic tumor	We sequenced tissue samples from patients with inflammatory myofibroblastic tumor, and then analyzed the data to explore molecular markers of this type of tumor, and provide assistance in the diagnosis and targeted therapy of the disease.	through study completion,an average of 1 year